Oncolytic adenoviral gene therapy in ovarian cancer: Why we are not wasting our time

Future Oncology

Volumn 5, Issue 3, 2009, Pages 339-357

  Young, A M ^a   McNeish, Iain A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adenovirus; Gene therapy; Intraperitoneal; Oncolytic virus; Ovarian cancer; P53; Retinoblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; DL 922 947; EPIRUBICIN; GEMCITABINE; H 101; ICODEXTRIN; ONCOLYTIC ADENOVIRUS; ONYX 015; PLATINUM DERIVATIVE; SCH 58500; UNCLASSIFIED DRUG;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADENOVIRUS; CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; DIARRHEA; DNA VIRUS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG TARGETING; FEVER; FLU LIKE SYNDROME; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; LIFE CYCLE; NAUSEA AND VOMITING; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS;

EID: 67049145240     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.11     Document Type: Review

References (150)

1. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukada Y, Emrich LJ: The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J. Clin. Oncol. 6, 983-989 (1988).
2. De Pace N: Sulla scomparsa di un enorme cancer vegetante del callo dell'utero senza cura chirurgica. Ginecologia 9, 82-88 (1912).
3. Bluming AZ, Ziegler JL: Regression of Burkitt's lymphoma in association with measles infection. Lancet 2, 105-106 (1971).
4. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF: Regression of Hodgkin's disease after measles. Lancet 1, 1112 (1981).
5. Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346-358 (2003).
6. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281 (1986).
7. Rainov NG: A Phase III clinical evaluation of herpes simplex virus type I thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389-2401 (2000).
8. Hawkins LK, Lemoine NR, Kirn D: Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol. 3, 17-26 (2002).
9. Everts B, van der Poel HG: Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 12, 141-161 (2005).
10. Barnes MN, Coolidge CJ, Hemminki A, Alvarez RD, Curiel DT: Conditionally replicative adenoviruses for ovarian cancer therapy. Mol. Cancer Ther. 1, 435-439 (2002).
11. Tubiana M, Malaise E: Growth rate and Cell kinetics in human tumours: some prognostic and therapeutic implications. In: Scientific Foundations of Oncology. Symington T, Carter RL (Eds). Heinemann, Oxford, UK, 126-136 (1976).
12. Shenk T, Adenoviridae: The Viruses and Their Replication. In: Fields Virology. Knipe D, Howley P (Eds). Lippincott Williams and Wilkins, PA, USA, 2265-2301 (2001).
13. Evans J: Adenoviral Replication. In: Adenoviral Vectors for Gene Therapy. Curiel D Douglas J (Eds), Academic-Press, London, UK, 39-70 (2002).
14. Berk AJ: Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24, 7673-7685 (2005).
15. Felsani A, Mileo AM, Paggi MG: Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 25, 5277-5285 (2006).
16. White E: Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 20, 7836-7846 (2001).
17. Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2, 103-112 (2002).
18. Martin ME, Berk AJ: Adenovirus E1B 55K represses p53 activation in vitro. J. Virol. 72, 3146-3154 (1998).
19. Shao R, Hu MC, Zhou BP et al.: E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of Iκβ kinases and nuclear factor κβ activities. J. Biol. Chem. 274, 21495-21498 (1999).
20. Routes JM, S Ryan, Clase A et al.: Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J. Immunol. 165, 4522-4527 (2000).
21. de Jong RN, van der Vliet PC, Brenkman AB: Adenovirus DNA replication: protein priming, jumping back and the role of the DNA binding protein DBP. Curr. Top Microbiol. Immunol. 272, 187-211 (2003).
22. Hermiston TW, Tripp RA, Sparer T, Gooding LR, Wold WS: Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytoroxic T lymphocytes. J. Virol. 67, 5289-5298 (1993a).
23. Hermiston TW, Hellwig R, Hierholzer JC, Wold WS: Sequence and functional analysis of the human adenovirus type 7 E3-gp19K protein from 17 clinical isolates. Virology 197, 593-600 (1993).
24. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS: Functions and mechanisms of action of the adenovirus E3 proteins. Int. Rev. Immunol. 23, 75-111 (2004).
25. Benedict CA, Norris PS, Prigozy TI et al.: Three adenovirus F3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J. Biol. Chem. 276, 327-3278 (2001).
26. Shisler J, Yang C, Walter B, Ware CF, Gooding LR: The adenovirus E3 - 10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J. Virol. 71 8299-8306 (1997).
27. Li Y, Lang J, Horwitz MS: Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor α-inducible cellular protein containing leucine zipper domains. Mol. Cell Biol. 18, 1601-1610 (1998).
28. Carmody RJ, Maguschak K, Chen YH: A novel mechanism of nuclear factor-κβ regulation by adenoviral protein 14.7K. Immunology 117, 188-195 (2006).
29. Krajcsi P, Dimitrov T, Hermiston TW et al.: The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J. Virol. 70, 4904-4913 (1996).
30. Mohr I: To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene 24, 7697-7709 (2005).
31. Weitzman MD: Functions of the adenovirus E4 proteins and their impact on viral vectors. Front. Biosci. 10, 1106-1117 (2005a).
32. Weitzman MD, Ornelles DA: Inactivating intracellular antiviral responses during adenovirus infection. Oncogene 24, 7686-7696 (2005b).
33. Halbert DN, Curt JR, Shenk T: Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J. Virol. 56, 250-257 (1985).
34. Ostapchuk P, Hearing P: Control of adenovirus packaging. J. Cell. Biochem. 96, 25-35 (2005).
35. Farley DC, Brown JL, Leppard KN: Activation of the early-late switch in adenovirus type 5 major late transcription unit expression by L4 gene products. J. Virol. 78, 1782-1791 (2004).
36. O'Shea CC, Johnson L, Bagus B et al.: Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611-623 (2004).
37. Huang JT, Schneider RJ: Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding protein. Cell 65, 271-280 (1991).
38. Mathews MB: Binding of adenovirus VA RNA to mRNA: a possible role in splicing? Nature 285, 575-577 (1980).
39. Logan J, Shenk T: Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. Proc. Natl Acad. Sci. USA 81, 3655-3659 (1984).
40. Chen PH, Ornelles DA, Shenk T: The adenovirus L3 23-kilodalton proteinase cleaves the amino-terminal head domain from cytokeratin 18 and disrupts the cytokeratin network of HeLa cells. J. Virol. 67, 3507-3514 (1993).
41. Tollefson AE SA, Hermiston TW, Ryerse JS, Wold LJ, Wold WS.: The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296-2306 (1996).
42. Ioannides CG, Platsoucas CD, Patenia R et al.: T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. Anticancer Res. 10, 645-653 (1990).
43. Righetti SC, G Della Torre, Pilotti S et al.: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56, 689-693 (1996).
44. Eliopoulos AG, Kerr DJ, Herod J et al.: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11, 1217-1228 (1995).
45. Yaginuma Y, Westphal H: Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 52, 4196-4199 (1992).
46. Buller RE, Runnebaum, IB, Karlan BY et al.: A Phase I/Il trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9, 553-566 (2002a).
47. Buller RE, Shahin MS, Horowitz JA et al.: Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 9, 567-572 (2002b).
48. Wen SF, Mahavni V, Quijano E et al.: Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus- p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 10, 224-238 (2003).
49. Zeimet AG, Marth C: Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4, 415-422 (2003).
50. Bischoff JR, Kirn DH, Williams A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376 (1996).
51. Yew PR, Kao CC, Berk AJ: Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis. Virology 179, 795-805 (1990).
52. Kao CC, Yew PR, Berk AJ: Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 179, 806-814 (1990).
53. Heise C, Hermiston T, Johnson L et al.: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134-1139 (2000a).
54. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW: p53-dependent cell death/ apoptosis is required for a productive adenovirus infection. Nat. Med. 4, 1068-1072 (1998).
55. Harada JN, Berk AJ: p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73, 5333-5344 (1999).
56. Goodrum ED, Ornelles DA: p53-status does not determine outcome of E1B 55-kilodalton mutant adenovirus lyric infection. J. Virol. 72, 9479-9490 (1998).
57. Z Ganly I, Kirn D, Eckhardt G et al.: A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806 (2000).
58. Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D: Efficacy of a replication-selective aderiovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther. 7, 1925-1929 (2000).
59. Vasey PA, Shulman LN, Campos S et al.: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus; ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20, 1562-1569 (2002).
60. Nemunaitis J, Ganly I, Khuri F et al.: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. 60, 6359-6366 (2000).
61. Nemunaitis J, Khuri F, Ganly I et al.: Phase II trial of intratumoral administration of ONYX-015, a replication-selectivc adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289-29rS (2001).
62. Dobbelstein M, Roth J, Kimberly WT, Levine AJ, Shenk T: Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence. EMBO J. 16, 4276-4284 (1997).
63. Helt AM, Galloway DA: Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24, 159-169 (2003).
64. Lockley M, Fernandez M, Wang Y et al.: Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res. 66, 989-998 (2006).
65. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins ανβ 3 and ανβ 5 promote adenovirus internalization but not virus attachment. Cell 73, 309-319 (1993).
66. Koizumi N, Kawabata K, Sakurai F, Watanabe Y, Hayakawa T, Mizuguchi H: Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, αν integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum. Gene Ther. 17, 264-279 (2006).
67. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A: Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79, 7478-7491 (2005).
68. Stone D, Liu Y, Shayakhmetov D, Li ZY, Ni S, Lieber A: Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J. Virol. 81, 4866-4871 (2007).
69. Zeimet AG, Muller-Holzner E, Schuler A et al.: Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther. 9, 1093-1100 (2002).
70. Kelly FJ, Miller CR, Buchsbaum DJ et al.: Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin. Cancer Res. 6, 4323-4333 (2000).
71. Mathis JM, Stoff-Khalili MA, Curiel DT: Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene 24, 7775-7791 (2005).
72. Green NK, Morrison J, Hale S et al.: Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J. Gene Med. 10, 280-289 (2008).
73. Morrison J, Briggs SS, Green N et al.: Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther. 16, 244-251 (2008).
74. Kanerva A, Mikheeva GV, Krasnykh V et al.: Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8, 275-280 (2002).
75. Kanerva A, Wang M, Bauerschmitz GJ et al.: Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5, 695-704 (2002).
76. Tsuruta Y, Pereboeva L, Glasgow JN et al.: A mosaic fiber adenovirus serotype 5 vector containing reovirus σ 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway. Clin. Cancer Res. 13, 2777-2783 (2007).
77. Fueyo J, Alemany R, Gomez-Manzano C et al.: Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl Cancer Inst. 95, 652-660 (2003).
78. Bauerschmitz GJ, Lam JT, Kanerva A et al.: Treatment of ovarian cancer with a tropism mbdified oncolytic adenovirus. Cancer Res. 62, 1266-1270 (2002).
79. Rocconi RP, Zhu ZB, M Stoff-Khalili et al.: Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol. Oncol. 105, 113-121 (2007).
80. Ko D, Hawkins L, Yu DC: Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 24, 7763-7774 (2005).
81. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytoroxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563 (1997).
82. DeWeese TL, van der Poel H, Li S et al.: A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464-7472 (2001).
83. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR: Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 61, 4961-4965 (2001).
84. Zhu ZB, Makhija SK, Lu B et al.: Transcriptional targeting of adenoviral vector through the CXCR4 rumor-specific promoter. Gene Ther. 11, 645-648 (2004).
85. Bauerschmitz GJ, Guse K, Kanerva A et al.: Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol. Ther. 14, 164-174 (2006).
86. Kanerva A, Bauerschmitz GJ, Yamamoto M et al.: A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther. 11, 552-559 (2004).
87. Hernaiz Driever P, Rabkin SD: Replication-competent viruses for cancer therapy. Monogr. Virol. Karger. 56-80 (2001).
88. Ryan PC, Jakubczak JL, Stewart DA et al.: Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther. 11, 555-569 (2004).
89. Lusky M: Good manufacturing practice production of adenoviral vectors for clinical trials. Hum. Gene Ther. 16, 281-291 (2005).
90. Working PK, Lin A, Borellini F: Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses. Oncogene 24, 7792-7801 (2005).
91. Speyer JL, Collins JM, Dedrick RL et al.: Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 40, 567-572 (1980).
92. Howell SB, Pfeifle CL, Wung WE et al.: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97, 845-851 (1982).
93. Rothenberg ML, Liu PY, Braly PS et al.: Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup Phase II trial. J. Clin. Oncol. 21, 1313-1319 (2003).
94. Armstrong DK, Bundy B, Wenzel L et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43 (2006).
95. Fujiwara K, Markman M, Morgan M, Coleman RL: Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol. Oncol. 97, 10-15 (2005).
96. Alberts DS, Liu PY, Hannigan EV et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950-1955 (1996).
97. Hosie K, Gilbert JA, Kerr D, Brown CB, Peers EM: Fluid dynamics in man of an intraperitoneal drug delivery solution: 4% icodextrin, Drug Deliv. 8, 9-12 (2001).
98. Hosie KB, Kerr DJ, Gilbert JA et al.: A pilot study of adjuvant intraperitoneal 5-fluorouracil using 4% icodextrin as a novel carrier solution. Eur. J. Surg. Oncol. 29, 254-260 (2003).
99. McArdle CS, Kerr DJ, O'Gorman P et al.: Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. Br. J. Cancer 70, 762-766 (1994).
100. Wolf JK, Bodurka DC, Gano JB et al.: A Phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol. Oncol. 94, 442-448 (2004).
101. Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH: Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 47, 269-276 (2001).
102. Engler H, Machemer TR, Schluep T et al.: Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice. Mol. Ther. 7, 558-564 (2003).
103. Rocconi RP, Numnum MT, Zhu ZB et al.: Icodexirin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy. Gynecol. Oncol. 103, 985-989 (2006).
104. Edinger M, Cao YA, Hornig YS et al.: Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur. J. Cancer 38, 2128-2136 (2002).
105. Contag CH, Spilman SD, Contag PR et al.: Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem. Photobiol. 66, 523-531 (1997).
106. Contag PR, Olomu IN, Stevenson DK, Contag CH: Bioluminescent indicators in living mammals. Nat. Med. 4, 245-247 (1998).
107. Leyton J, Lockley M, Aerts JL et al.: Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography imaging. Cancer Res. 66, 9178-9185 (2006).
108. Raper SE, Yudkoff M, Chirmule N et al.: A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 13, 163-175 (2002).
109. Small EJ, Carducci MA, Burke JM et al.: A Phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 14, 1017-117 (2006).
110. Lohr F, Huang Q, Hu K, Dewhirst MW, Li CY: Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clin. Cancer Res. 7, 3625-3628 (2001).
111. Sauthoff H, Hu J, Maca C et al.: Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persisrs and spreads systemically at late time points. Hum. Gene Ther. 14, 425-433 (2003).
112. Wang Y, Hu JK, Krol A, Li YP, Li CY, Yuan F: Systemic dissemination of viral vectors during intratumoral injection. Mol. Cancer Ther. 2, 1233-1242 (2003).
113. Heise CC, Williams AM, Xue S, Propst M, Kirn DH: Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59, 2623-2628 (1999).
114. Johnson L, Shen A, Boyle L et al.: Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1, 325-337 (2002).
115. Alemany R, Suzuki K, Curiel DT: Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81, 2605-2609 (2000).
116. Muruve DA: The innate immune response to adenovirus vectors. Hum. Gene Ther. 15, 1157-1166 (2004).
117. Lieber A, He CY, Meuse L et al.: The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71, 8798-8807 (1997).
118. Manickan E, Smith JS, Tian J et al.: Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol. Ther. 13, 108-117 (2006).
119. Tao N, Gao GP, Parr M et al.: Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3, 28-35 (2001).
120. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, Crystal RG: Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J. Virol. 71, 624-629 (1997).
121. Alemany R, Curiel DT: CAR-binding ablation does not change biodistribution and toxicity of adenioviral vectors. Gene Ther. 8, 1347-1353 (2001).
122. Smith TA, Idamakanti N, Rollence ML et al.: Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 14, 777-787 (2003).
123. Parker AL, McVey JH, Doctor JH et al.: Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J. Virol. 81, 3627-3631 (2007).
124. Waddington SN, Parker AL, Havenga M et al.: Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J. Virol. 81, 9568-9571 (2007).
125. Waddington SN, McVey JH, Bhella D et al.: Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409 (2008).
126. Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG: Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol. Ther. 6, 287-297 (2002).
127. Miller G, Lahrs S, Pillarisetty VG; Shah AB, DeMatteo RP: Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res. 62, 5260-5266 (2002).
128. Chen MJ, Holskin B, Strickler J et al.: Induction by E1A oncogene expression of cellular susceptibility to lysis by TNF. Nature 330, 581-583 (1987).
129. Cook JL, May DL, Wilson BA et al.: Role of tumor necrosis factor-α in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages. J Immunol. 142, 4527-4534 (1989).
130. Engler H, Machemer T, Philopena J et al.: Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-α. Virology 328, 52-61 (2004).
131. Shashkova EV, Do,onin K, Senac JS, Barry MA: Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res. 68, 5896-5904 (2008).
132. Suzuki K, Alemany R, Yamamoto M, Curiel DT: The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin. Cancer Res. 8, 3348-3359 (2002).
133. Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH: ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther. 12, 61-71 (2005).
134. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA: Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 27, 3081-3090 (2008).
135. Abou El Hassan MA, van der Meulen-Muileman I, Abbas S, Kruyt FA: Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J. Virol. 78, 12243-12251 (2004).
136. Ito H, Aoki H, Kuhnel F et al.: Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J. Natl Cancer Inst. 98, 625-636 (2006).
137. Heise C, Lemmon M, Kirn D: Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin. Cancer Res. 6, 4908-4914 (2000).
138. Raki M, Sarkioja M, Desmond RA et al.: Oncolytic adenovirus Ad5/ 3-δ24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol. Oncol. 108, 166-172 (2008).
139. Janeway C, Travers P, Walport M, Sclomik M.: Immunobiology. The Immune System in Health and Disease (6th edition). Garland Science Publishing, Oxford, UK (2005).
140. Park SM, Schickel R, Peter ME: Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr. Opin. Cell Biol. 17, 610-616 (2005).
141. Schneider-Brachert W, Tchikov V, Merkel O et al.: Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. J. Clin. Invest. 116, 2901-2913 (2006).
142. Lichtenstein DL, Doronin K, Toth K, Kuppuswamy M, Wold WS, Tollefson AE: Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2. J. Virol. 78, 12297-12307 (2004).
143. Liu TC, Hallden G, Wang Y et al.: An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol. Ther. 9, 786-803 (2004).
144. Liu TC, Wang Y, Hallden G et al.: Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther. 12, 1333-1346 (2005).
145. Blair GE, Dixon SC, Griffiths SA, Zajdel ME: Restricted replication of human adenovirus type 5 in mouse cell lines. Virus Res. 14, 339-346 (1989).
146. Ganly I, Mautner V, Balmain A: Productive replication of human adenoviruses in mouse epidermal cells. J. Virol. 74, 2895-2899 (2000).
147. Hallden G, Hill R, Wang Y et al.: Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol. Ther. 8, 412-424 (2003).
148. Wang Y, Hallden G, Hill R et al.: E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat. Biotehnol. 21, 1328-1335 (2003).
149. Jogler C, Hoffmann D, Theegarten D, Grunwald T, Uberla K, Wildner O: Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J. Virol. 80, 3549-3558 (2006).
150. Hemminki A, Kanerva A, Kremer EJ et al.: A canine conditionally replicating adenovirus for evaluating oncolycic virotherapy in a syngeneic animal model. Mol. Ther. 7, 163-173 (2003).